Company Study Aims to Determine Efficacy of Diabetes Treatment LAS VEGAS, NV--(Marketwired - Jul 7, 2015) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company") is pleased to announce that efforts are underway to commence clinical trials of its innovative and proprietary technology branded under the trade name e-Balance. Designed for the treatment of diabetes, the intent of the upcoming trials is to accurately measure and quantify e-Balance's ability to alter key metabolic pathways targeting improved blood sugar control. Dr. John Sanderson, Cell MedX Chief Medical Officer, is assembling a team of nurses and clinicians as well as a cohort of volunteer diabetic patients in preparation...
↧